Clinical trials: Acute STEMI
Reperfusion Injury, STEMI
Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
The EMBRACE-STEMI trial was a Phase 2a prospective, multicenter, multinational randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of IV administered elamipretide (also…
- Trial name
- EMBRACE (NCT01572909)
- Testing
- Bendavia (MTP-131)
- Where
- 30 sites in United States, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Stealth BioTherapeutics Inc.
Acute Coronary Syndromes
A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction
The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary…
- Trial name
- ACCOAST (NCT01015287)
- Testing
- Prasugrel
- Where
- 153 sites in Austria, Belgium and 17 more
- Volunteers
- 4,033 people
- Sponsor
- Eli Lilly and Company
Acute Coronary Syndrome (ACS)
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.
- Trial name
- NCT03672097
- Testing
- Prasugrel
- Where
- 10 sites in Taiwan
- Volunteers
- 204 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Acute ST Segment Elevation Myocardial Infarction
Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
The goal of the study was to evaluate the effect of single administration of RPH-104 at 80 mg and 160 mg on parameters of systemic inflammation and outcomes of the disease in subjects with ST-segment elevation myocardial…
- Trial name
- NCT04463251
- Testing
- RPH-104 80 mg
- Where
- 11 sites in United States, Russia
- Volunteers
- 102 people
- Sponsor
- R-Pharm Overseas, Inc.
Acute Myocardial Infarction
Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)
This study will evaluate change in heart muscle function from baseline to three months and twelve months in participants who present with a heart attack and a completely occluded coronary artery.
- Trial name
- NCT01324453
- Testing
- Post Conditioning + Primary PCI, Standard Primary PCI
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Minneapolis Heart Institute Foundation
Myocardial Infarction, Reperfusion Injury
Pilot Study of Edaravone to Treat Acute Myocardial Infarction
Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries.
- Trial name
- NCT00265239
- Testing
- edaravone
- Where
- Japan
- Volunteers
- 104 people
- Sponsor
- Kumamoto University
Acute Coronary Syndrome
A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation
This is a randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate initial safety and efficacy of GW856553 in subjects with NSTEMI.
- Trial name
- Solstice (NCT00910962)
- Testing
- GW856553
- Where
- 108 sites in United States, Australia and 7 more
- Volunteers
- 526 people
- Sponsor
- GlaxoSmithKline
Non ST Elevation Myocardial Infarction
Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up
1. INTRODUCTION Through last couple of years the number of patients treated for acute coronary event without persistent ST segment elevation in ECG has been growing.
- Trial name
- NCT01863134
- Testing
- Eptifibatide
- Where
- 6 sites in United States, Poland
- Volunteers
- 140 people
- Sponsor
- Medical University of Silesia
Acute ST Segment Elevation Myocardial Infarction
Platelet Function in Resuscitated Patients
Approx. 65% of resuscitated patients at the intensive care unit for internal medicine are due to myocardial infarction. Almost all patients are initially diagnosed and treated in the cath lab.
- Trial name
- NCT02914795
- Testing
- diagnostic analysis of platelet function
- Where
- Austria
- Volunteers
- 99 people
- Sponsor
- Medical University of Graz
Acute Myocardial Infarction, STEMI
A Study of Acute Myocardial Infarction Using FDY-5301
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of three dose levels of FDY-5301 compared to placebo in STEMI patients undergoing PCI.
- Trial name
- NCT03470441
- Testing
- FDY-5301
- Where
- 23 sites in United States, Hungary and 2 more
- Volunteers
- 120 people
- Sponsor
- Faraday Pharmaceuticals, Inc.
Heart Attack
P3AMI Antiplatelet Trial
Major heart attacks are caused by a numerous factors, including sudden clot formation in a coronary artery leading to a blockage and heart muscle death. The clots are largely made of sticky clotting blood cells (platelets).
- Trial name
- NCT02376283
- Testing
- Prasugrel, Clopidogrel, ticagrelor
- Where
- United Kingdom
- Volunteers
- 87 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Acute Myocardial Infarction
Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)
VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI) measuring the effects on the acute rise and fall…
- Trial name
- VCU-ART3 (NCT01950299)
- Testing
- Anakinra 100 mg
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Virginia Commonwealth University
Acute ST Elevation Myocardial Infarction
REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction
The purpose of this study is to evaluate whether erythropoietin can help limit the damage to the heart in patients with acute heart attacks.
- Trial name
- NCT00378352
- Testing
- Epoetin alfa
- Where
- 16 sites in United States
- Volunteers
- 223 people
- Sponsor
- National Institute on Aging (NIA)
Acute Myocardial Infarction
A Safety/Efficacy Study of Intra-coronary Tenecteplase During Balloon Angioplasty to Treat Heart Attacks
The primary objective of this study is to gather preliminary data regarding the angiographic efficacy of the administration of low-dose adjunctive intracoronary (IC) tenecteplase during balloon angioplasty for heart attacks.
- Trial name
- ICE T-TIMI 49 (NCT00604695)
- Testing
- Tenecteplase, Sterile Saline
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- C. Michael Gibson, MS, MD
Myocardial Infarction, Acute Coronary Syndrome
Diagnostic Accuracy of Electrocardiogram for Acute Coronary Occlusion Resulting in Myocardial Infarction
The decision of emergency reperfusion of a suspected acute coronary artery occlusion by means of percutaneous coronary intervention or intravenous thrombolytics depends on the presence of a certain amount of ST-segment elevation…
- Conditions
- Myocardial Infarction, Acute Coronary Syndrome, Coronary Artery Disease
- Trial name
- DIFOCCULT (NCT04022668)
- Testing
- Coronary angiogram
- Where
- Turkey (Türkiye)
- Volunteers
- 3,000 people
- Sponsor
- Yeditepe University
Acute Myocardial Infarction, ST Elevation MI
Nitric Oxide in Myocardial Infarction Size
The purpose of this study is to assess whether or not inhaled nitric oxide can decrease myocardial infarction (MI) size at 48-72 hours in patients presenting with an ST segment elevation MI (STEMI) who undergo successful…
- Conditions
- Acute Myocardial Infarction, ST Elevation MI, STEMI
- Trial name
- NOMI (NCT00568061)
- Testing
- Nitric Oxide
- Where
- 14 sites in United States, Belgium and 1 more
- Volunteers
- 29 people
- Sponsor
- Mallinckrodt
Acute Anterior Myocardial Infarction
The INFUSE - Anterior Myocardial Infarction (AMI) Study
This is a multicenter, open-label, controlled, single-blind, randomized study with up to 452 subjects enrolled in up to 50 US and European sites.
- Trial name
- NCT00976521
- Testing
- Abciximab local infusion, No local infusion, Thrombus aspiration
- Where
- 38 sites in United States, Austria and 4 more
- Volunteers
- 452 people
- Sponsor
- Atrium Medical Corporation
STEMI
Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI
The primary objective of this study is to assess whether an aggressive quality improvement intervention strategy will decrease time from hospital presentation to first balloon inflation in non-transfer patients with acute ST…
- Trial name
- RAPID-PCI (NCT01625104)
- Testing
- Non Intervention, Agressive Intervention Process Improvement Strategies
- Where
- United States
- Volunteers
- 882 people
- Sponsor
- University of Michigan
AMI
Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction
Primary objective: To demonstrate that in hyperglycemic subjects with anterior STEMI (ST Elevation Myocardial Infarction) undergoing Percutaneous Coronary Intervention (PCI), tight glycemic control using insulin glulisine and…
- Trial name
- INTENSIVE (NCT00670228)
- Testing
- Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy
- Where
- 5 sites in United States, Argentina and 3 more
- Volunteers
- 34 people
- Sponsor
- Sanofi
Myocardial Infarction
Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack
The study will evaluate the effect of BB3 to preserve myocardial (heart) tissue and function following myocardial infarction (heart attack).
- Trial name
- NCT01539590
- Testing
- BB3, Normal saline
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Angion Biomedica Corp